ページ内を移動するためのリンクです。

Financial Highlights

Key Results (Tables)Click to view graphs.

Consolidated Financial Data (JPY billion / % change)

  FY2009 FY2010 FY2011 FY2012 FY2013
Net Sales 1,084.3 1,127.6 1,154.6 1,218.1 1,452.8
13.4% 4.0% 2.4% 5.5% 19.3%
Operating Income 98.5 126.3 148.7 169.7 198.7
7.6% 28.2% 17.7% 14.1% 17.1%
Ordinary Income 109.1 128.4 152.1 184.5 215.2
13.5% 17.7% 18.5% 21.3% 16.7%
Net Income 67.4 82.4 92.2 122.4 151.0
43.2% 22.1% 11.9% 32.8% 23.3%
Research and Development
Expenditure
151.8 164.7 159.2 192.4 249.0
11.7% 8.4% -3.3% 20.8% 29.4%
  FY2009 FY2010 FY2011 FY2012 FY2013
Total Assets 1,458.4 1,589.7 1,666.8 1,779.2 2,028.4
Net Assets 948.5 1,163.3 1,222.8 1,325.1 1,510.8
Equity Capital Ratio 64.2 72.4 72.5 73.7 73.2

From 1QFY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate.The method of presentation for upfront licensing payments received was changed from non-operating income to net sales.Figures for FY2010 have been adjusted retrospectively to apply the changes above.

Geographical Segment Sales

  FY2013 (JPY billion) % of Net Sales
Japan 628.3 43.2
North America 599.6 41.3
Others 224.9 15.5

Sales by Business Segment

  FY2013 (JPY billion) % of Net Sales
Pharmaceutical business 1,035.1 71.2
Nutraceutical business 281.1 19.4
Consumer products business 43.8 3.0
Other business 92.8 6.4

Key Management Indicators

  FY2009 FY2010 FY2011 FY2012 FY2013
ROE (Return on equity: %) 7.7% 7.9% 7.8% 9.7% 10.8%
EPS (Earnings per share: yen) 143.5 164.5 165.2 221.9 278.1
Annual dividends per share (yen) 12.5 28.0 45.0 58.0 65.0
Payout ratio (%) 8.7% 17.3% 27.2% 26.1% 23.4%

Key Results (Graphs)Click to view tables.

  • Graph:Net Sales

  • Graph:Operating Income

  • Graph:Ordinary Income

  • Graph:Research and Development Expenditure

  • Graph:Geographical Segment Sales

  • Sales by Business Segment